Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

References

• LoftusEVJrClinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influencesGastroenterology200412661504151715168363
   PubMed Web of Science ®Google Scholar
• CalkinsBMMendeloffAIEpidemiology of inflammatory bowel diseaseEpidemiol Rev1986860913533585
   PubMed Web of Science ®Google Scholar
• ShivanandaSLennard-JonesJLoganRIncidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)Gut19963956906979014768
   PubMed Web of Science ®Google Scholar
• KappelmanMDRifas-ShimanSLKleinmanKThe prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United StatesClin Gastroenterol Hepatol20075121424142917904915
   PubMed Web of Science ®Google Scholar
• RieglerGTartaglioneMTCarratuRAge-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group)Dig Dis Sci200045346246510749318
   PubMed Web of Science ®Google Scholar
• XavierRJPodolskyDKUnravelling the pathogenesis of inflammatory bowel diseaseNature2007448715242743417653185
   PubMed Web of Science ®Google Scholar
• BaumgartDCCardingSRInflammatory bowel disease: cause and immunobiologyLancet200736995731627164017499605
   PubMed Web of Science ®Google Scholar
• AggarwalSGhilardiNXieMHde SauvageFJGurneyALInterleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17J Biol Chem200327831910191412417590
   PubMed Web of Science ®Google Scholar
• HueSAhernPBuonocoreSInterleukin-23 drives innate and T cell-mediated intestinal inflammationJ Exp Med2006203112473248317030949
   PubMed Web of Science ®Google Scholar
• KobayashiTOkamotoSHisamatsuTIL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s diseaseGut200857121682168918653729
   PubMed Web of Science ®Google Scholar
• BaiALuNGuoYLiuZChenJPengZAll-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitisJ Leukoc Biol200986495996919477911
   PubMed Web of Science ®Google Scholar
• RovedattiLKudoTBiancheriPDifferential regulation of interleukin-17 and interferon-{gamma} production in inflammatory bowel diseaseGut2009
   Web of Science ®Google Scholar
• LiuZJiuJLiuSFaXLiFDuYBlockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretionJ Autoimmun2007292–318719417804196
   PubMed Web of Science ®Google Scholar
• KornbluthASacharDBUlcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters CommitteeAm J Gastroenterol20049971371138515233681
   PubMed Web of Science ®Google Scholar
• CarswellEAOldLJKasselRLGreenSFioreNWilliamsonBAn endotoxin-induced serum factor that causes necrosis of tumorsProc Natl Acad Sci U S A1975729366636701103152
   PubMed Web of Science ®Google Scholar
• BradleyJRTNF-mediated inflammatory diseaseJ Pathol2008214214916018161752
   PubMed Web of Science ®Google Scholar
• MurchSHBraeggerCPWalker-SmithJAMacDonaldTTLocation of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel diseaseGut19933412170517098031350
   PubMed Web of Science ®Google Scholar
• BraeggerCPNichollsSMurchSHStephensSMacDonaldTTTumour necrosis factor alpha in stool as a marker of intestinal inflammationLancet1992339878589911345871
   PubMed Web of Science ®Google Scholar
• MurchSHLamkinVASavageMOWalker-SmithJAMacDonaldTTSerum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel diseaseGut19913289139171885073
   PubMed Web of Science ®Google Scholar
• BrynskovJFoeghPPedersenGTumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseaseGut2002511374312077089
   PubMed Web of Science ®Google Scholar
• KnightDMTrinhHLeJConstruction and initial characterization of a mouse-human chimeric anti-TNF antibodyMol Immunol19933016144314538232330
   PubMed Web of Science ®Google Scholar
• EbertECInfliximab and the TNF-alpha systemAm J Physiol Gastrointest Liver Physiol20092963G612G62019136378
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA approval of infliximab for Crohn’s disease http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327htm,1998
   Google Scholar
• WeissKDFood and Drug Administration Approval for Rheumatoid Arthritis http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107720pdf,1999
   Google Scholar
• KlotzUTemlASchwabMClinical pharmacokinetics and use of infliximabClin Pharmacokinet200746864566017655372
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA approval of infliximab for ulcerative colitis http://www.fda.gov/Drugs/DevelopmentApproval-Process/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/FastTrackApprovalReports/ucm082380htm,2006
   Google Scholar
• European Medicines AgencyEMEA approval of infliximab for Crohn’s disease and Rheumatoid Arthritis http://www.emea.europa.eu/humandocs/Humans/EPAR/remicade/remicadeM2htm,2009
   Google Scholar
• European Medicines AgencyEMEA approval of infliximab in Ulcerative Colitis http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/remicade-H-240-II-65-SDpdf,2006
   Google Scholar
• CornillieFShealyDD’HaensGInfliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s diseaseAliment Pharmacol Ther200115446347311284774
   PubMed Web of Science ®Google Scholar
• MoriSA relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapyMod Rheumatol2007172839117437161
   PubMedGoogle Scholar
• RutgeertsPD’HaensGTarganSEfficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s diseaseGastroenterology1999117476176910500056
   PubMed Web of Science ®Google Scholar
• MenachemYAvidanBLavyAIncreasing the infliximab dose is beneficial in Crohn’s disease patients who responded to a lower dose and relapsedDigestion2005722–312412816172549
   PubMed Web of Science ®Google Scholar
• TarganSRHanauerSBVan DeventerSJA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study GroupN Engl J Med199733715102910359321530
   PubMed Web of Science ®Google Scholar
• LugeringASchmidtMLugeringNPauelsHGDomschkeWKucharzikTInfliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathwayGastroenterology200112151145115711677207
   PubMed Web of Science ®Google Scholar
• Van Den BrandeJMBraatHVan Den BrinkGRInfliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s diseaseGastroenterology200312471774178512806611
   PubMed Web of Science ®Google Scholar
• AgnholtJKaltoftKInfliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn’s diseaseCytokine200115421222211563881
   PubMed Web of Science ®Google Scholar
• DaneseSSansMScaldaferriFTNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s diseaseJ Immunol200617642617262416456024
   PubMed Web of Science ®Google Scholar
• AgnholtJKelsenJBrandsborgBJakobsenNODahlerupJFIncreased production of granulocyte-macrophage colony-stimulating factor in Crohn’s disease–a possible target for infliximab treatmentEur J Gastroenterol Hepatol200416764965515201577
   PubMed Web of Science ®Google Scholar
• SuenaertPBulteelVLemmensLAnti-tumor necrosis factor treatment restores the gut barrier in Crohn’s diseaseAm J Gastroenterol20029782000200412190167
   PubMed Web of Science ®Google Scholar
• GoedkoopAYKraanMCPicavetDIDeactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre studyArthritis Res Ther200464R326R33415225368
   PubMed Web of Science ®Google Scholar
• D’AlessandriaCMalviyaGViscidoAUse of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn’s disease: in vitro and in vivo studiesQ J Nucl Med Mol Imaging200751433434217464276
   PubMed Web of Science ®Google Scholar
• NikolausSRaedlerAKuhbackerTSf ikasNFolschURSchreiberSMechanisms in failure of infliximab for Crohn’s diseaseLancet200035692401475147911081530
   PubMed Web of Science ®Google Scholar
• NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsInflamm Bowel Dis200713111323133217636564
   PubMed Web of Science ®Google Scholar
• SandbornWJHanauerSBKatzSEtanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trialGastroenterology200112151088109411677200
   PubMed Web of Science ®Google Scholar
• ScallonBCaiASolowskiNBinding and functional comparisons of two types of tumor necrosis factor antagonistsJ Pharmacol Exp Ther2002301241842611961039
   PubMed Web of Science ®Google Scholar
• VudattuNKHollerEEwingPReverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cellsImmunology2005115453654316011522
   PubMed Web of Science ®Google Scholar
• ZhangHYanDShiXTransmembrane TNF-alpha mediates “forward” and “reverse” signaling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cellsJ Leukoc Biol200884378979718550789
   PubMed Web of Science ®Google Scholar
• SandsBETremaineWJSandbornWJInfliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot studyInflamm Bowel Dis200172838811383595
   PubMed Web of Science ®Google Scholar
• ProbertCSHearingSDSchreiberSInfliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trialGut2003527998100212801957
   PubMed Web of Science ®Google Scholar
• JarnerotGHertervigEFriis-LibyIInfliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled studyGastroenterology200512871805181115940615
   PubMed Web of Science ®Google Scholar
• GustavssonAA 2-year follow-up of the Swedish-Danish Infliximab/Placebo trial in steroid resistant acute ulcerative colitisGastroenterology20071324A983
   Web of Science ®Google Scholar
• ArmuzziADePBLupascuAInfliximab in the treatment of steroid-dependent ulcerative colitisEur Rev Med Pharmacol Sci20048523123315638236
   PubMedGoogle Scholar
• OchsenkuhnTSackmannMGokeBInfliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot studyEur J Gastroenterol Hepatol200416111167117115489577
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPFeaganBGColectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabGastroenterology2009
   Google Scholar
• MossACFarrellRJInfliximab for induction and maintenance therapy for ulcerative colitisGastroenterology200613151649165117067595
   PubMedGoogle Scholar
• KaserAMairingerTVogelWTilgHInfliximab in severe steroid-refractory ulcerative colitis: a pilot studyWien Klin Wochenschr200111323–2493093311802508
   PubMed Web of Science ®Google Scholar
• CheyWYHussainARyanCPotterGDShahAInfliximab for refractory ulcerative colitisAm J Gastroenterol20019682373238111513177
   PubMed Web of Science ®Google Scholar
• ActisGCBrunoMPinna-PintorMRossiniFPRizzettoMInfliximab for treatment of steroid-refractory ulcerative colitisDig Liver Dis200234963163412405249
   PubMedGoogle Scholar
• KohnAPranteraCPeraACosintinoRSostegniRDapernoMInfliximab in the treatment of severe ulcerative colitis: a follow-up studyEur Rev Med Pharmacol Sci20048523523715638237
   PubMedGoogle Scholar
• Yamamoto-FurushoJKUzcangaLFInfliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroidsDig Surg200825538338619005257
   PubMed Web of Science ®Google Scholar
• AratariAPapiCClementeVColectomy rate in acute severe ulcerative colitis in the infliximab eraDig Liver Dis2008401082182618472316
   PubMedGoogle Scholar
• SuCSalzbergBALewisJDEfficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisAm J Gastroenterol200297102577258412385442
   PubMed Web of Science ®Google Scholar
• Gonzalez-LamaYFernandez-BlancoILopez-SanromanAOpen-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of responseHepatogastroenterology20085586–871609161419102352
   PubMedGoogle Scholar
• WillertRPLawranceICUse of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitisWorld J Gastroenterol200814162544254918442203
   PubMed Web of Science ®Google Scholar
• MaserEADecondaDLichtigerSUllmanTPresentDHKornbluthACyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitisClin Gastroenterol Hepatol20086101112111618928936
   PubMed Web of Science ®Google Scholar
• ManosaMLopez SanRAGarcia-PlanellaEInfliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitisDigestion2009801303519439969
   PubMed Web of Science ®Google Scholar
• GisbertJPGonzalez-LamaYMateJSystematic review: Infliximab therapy in ulcerative colitisAliment Pharmacol Ther2007251193717229218
   PubMed Web of Science ®Google Scholar
• RahimiRNikfarSAbdollahiMMeta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroidsMed Sci Monit2007137I13I18
   Web of Science ®Google Scholar
• LawsonMMThomasAGAkobengAKTumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitisCochrane Database Syst Rev20063CD00511216856078
   PubMedGoogle Scholar
• CheifetzAMayerLMonoclonal antibodies, immunogenicity, and associated infusion reactionsMt Sinai J Med200572425025616021319
   PubMedGoogle Scholar
• MossACFernandez-BeckerNJoKKCuryDCheifetzASThe impact of infliximab infusion reactions on long-term outcomes in patients with Crohn’s diseaseAliment Pharmacol Ther200828222122718485127
   PubMed Web of Science ®Google Scholar
• CheifetzASmedleyMMartinSThe incidence and management of infusion reactions to infliximab: a large center experienceAm J Gastroenterol20039861315132412818276
   PubMed Web of Science ®Google Scholar
• LichtensteinGRFeaganBGCohenRDSerious infections and mortality in association with therapies for Crohn’s disease: TREAT registryClin Gastroenterol Hepatol20064562163016678077
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJBuchanIMattesonELMontoriVAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trialsJAMA2006295192275228516705109
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345151098110411596589
   PubMed Web of Science ®Google Scholar
• SlifmanNRGershonSKLeeJHEdwardsETBraunMMListeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agentsArthritis Rheum200348231932412571839
   PubMed Web of Science ®Google Scholar
• EsteveMSaroCGonzalez-HuixFSuarezFForneMViverJMChronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxisGut20045391363136515306601
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA announce black box warning for invasive fungal infections in patients on anti-TNF medications http://wwwfdagov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109340htm,2008
   Google Scholar
• BrownSLGreeneMHGershonSKEdwardsETBraunMMTumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug AdministrationArthritis Rheum200246123151315812483718
   PubMed Web of Science ®Google Scholar
• AsklingJForedCMBaecklundEHaematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnn Rheum Dis200564101414142015843454
   PubMed Web of Science ®Google Scholar
• SiegelCAMardenSMPersingSMLarsonRJSandsBERisk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysisClin Gastroenterol Hepatol20097887488119558997
   PubMed Web of Science ®Google Scholar
• KandielAFraserAGKorelitzBIBrensingerCLewisJDIncreased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurineGut20055481121112516009685
   PubMed Web of Science ®Google Scholar
• MackeyACGreenLLiangLCDinndorfPAviganMHepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel diseaseJ Pediatr Gastroenterol Nutr200744226526717255842
   PubMed Web of Science ®Google Scholar
• ShaleMKanferEPanaccioneRGhoshSHepatosplenic T cell lymphoma in inflammatory bowel diseaseGut200857121639164118667489
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA black box warning of lymphoma and malignancy in children treated with anti-TNF http://wwwfdagov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474htm,2009
   Google Scholar
• WolfeFMichaudKBiologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational studyArthritis Rheum20075692886289517729297
   PubMed Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med2003348760160812584368
   PubMed Web of Science ®Google Scholar
• MaserEAVillelaRSilverbergMSGreenbergGRAssociation of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s diseaseClin Gastroenterol Hepatol20064101248125416931170
   PubMed Web of Science ®Google Scholar
• MorIJVogelJDda LuzMAShenBHammelJRemziFHInfliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomyDis Colon Rectum20085181202120718536964
   PubMed Web of Science ®Google Scholar
• SelvasekarCRCimaRRLarsonDWEffect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitisJ Am Coll Surg2007204595696217481518
   PubMed Web of Science ®Google Scholar
• MohanNEdwardsETCuppsTRDemyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritidesArthritis Rheum200144122862286911762947
   PubMed Web of Science ®Google Scholar
• ChungESPackerMLoKHFasanmadeAAWillersonJTRandomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trialCirculation2003107253133314012796126
   PubMed Web of Science ®Google Scholar
• LichtensteinGRHanauerSBSandbornWJManagement of Crohn’s disease in adultsAm J Gastroenterol2009104246548319174807
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization PracticesUse on Influenza A(H1N1) 2009 Monovalent Vaccine http://wwwcdcgov/mmwr/preview/mmwrhtml/rr58e0821a1htm, 9 A.D.
   Google Scholar
• Centers for Disease Control and PreventionRecommended adult immunization schedule – United StatesMMWR20085753 http://wwwcdcgov/mmwr/PDF/wk/mm5753-Immunizationpdf, 9 A.D.
   Google Scholar
• KaneSShayaFMedication non-adherence is associated with increased medical health care costsDig Dis Sci20085341020102417934828
   PubMed Web of Science ®Google Scholar
• KaneSHuoDAikensJHanauerSMedication nonadherence and the outcomes of patients with quiescent ulcerative colitisAm J Med20031141394312543288
   PubMed Web of Science ®Google Scholar
• KaneSDixonLAdherence rates with infliximab therapy in Crohn’s diseaseAliment Pharmacol Ther20062471099110316984504
   PubMed Web of Science ®Google Scholar
• CurkendallSPatelVGleesonMCampbellRSZagariMDuboisRCompliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?Arthritis Rheum200859101519152618821651
   PubMed Web of Science ®Google Scholar
• GrijalvaCGChungCPArbogastPGSteinCMMitchelEFJrGriffinMRAssessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritisMed Care20074510 Supll 2S66S7617909386
   PubMed Web of Science ®Google Scholar
• IrvineEJQuality of life of patients with ulcerative colitis: past, present, and futureInflamm Bowel Dis200814455456517973299
   PubMed Web of Science ®Google Scholar
• MarteauPPooleCNielsenSCurrieCQuality of life (health-related utility) in adults with uicerative colitis in remission v’s mild/moderate and severe relapse: findings from the PODIUM StudyCDDW (abstract 193) http://www.pulsus.com/cddw2009/abs/193htm,2009
   Google Scholar
• BernklevTJahnsenJSchulzTCourse of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosisEur J Gastroenterol Hepatol200517101037104516148548
   PubMed Web of Science ®Google Scholar
• FeaganBGReinischWRutgeertsPThe effects of infliximab therapy on health-related quality of life in ulcerative colitis patientsAm J Gastroenterol2007102479480217324131
   PubMed Web of Science ®Google Scholar
• LeungYPanaccioneRHemmelgarnBJonesJExposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitisDig Dis Sci20085361455146117932752
   PubMed Web of Science ®Google Scholar
• TimmerAMcDonaldJWMacdonaldJKAzathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitisCochrane Database Syst Rev20071CD00047817253451
   PubMed Web of Science ®Google Scholar
• OrenRMoshkowitzMOdesSMethotrexate in chronic active Crohn’s disease: a double-blind, randomized, Israeli multicenter trialAm J Gastroenterol19979212220322099399753
   PubMed Web of Science ®Google Scholar
• PaoluziOAPicaRMarcheggianoAAzathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remissionAliment Pharmacol Ther200216101751175912269968
   PubMed Web of Science ®Google Scholar
• LichtigerSPresentDHKornbluthACyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med199433026184118458196726
   PubMed Web of Science ®Google Scholar
• VanAGD’HaensGNomanMRandomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitisGastroenterology200312541025103114517785
   PubMed Web of Science ®Google Scholar
• CohenRDSteinRHanauerSBIntravenous cyclosporin in ulcerative colitis: a five-year experienceAm J Gastroenterol19999461587159210364029
   PubMed Web of Science ®Google Scholar
• MoskovitzDNVanAGMaenhoutBIncidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitisClin Gastroenterol Hepatol20064676076516716758
   PubMed Web of Science ®Google Scholar
• SternthalMBMurphySJGeorgeJKornbluthALichtigerSPresentDHAdverse events associated with the use of cyclosporine in patients with inflammatory bowel diseaseAm J Gastroenterol2008103493794318177449
   PubMed Web of Science ®Google Scholar
• MossACPeppercornMASteroid-refractory severe ulcerative colitis: what are the available treatment options?Drugs20086891157116718547130
   PubMed Web of Science ®Google Scholar
• MeierCBHegaziRAAisenbergJInnate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor?Inflamm Bowel Dis2005111196597116239841
   PubMed Web of Science ®Google Scholar
• LohmullerJLPembertonJHDozoisRRIlstrupDVanHJPouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosisAnn Surg199021156226272339922
   PubMed Web of Science ®Google Scholar
• FerranteMDeclerckSDeHGOutcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitisInflamm Bowel Dis2008141202817973304
   PubMed Web of Science ®Google Scholar
• KeranenULuukkonenPJarvinenHFunctional results after restorative proctocolectomy complicated by pouchitisDis Colon Rectum19974077647699221849
   PubMed Web of Science ®Google Scholar
• ColombelJFRutgeertsPReinischWMantzarisGJKornbluthASONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapyJournal of Crohn’s and Colitis200931S45S46
   Google Scholar
• LichtigerSTreatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporineInflamm Bowel Dis200915114114218266232
   PubMed Web of Science ®Google Scholar
• D’HaensGInfliximab for ulcerative colitis: finally some answersGastroenterology200512872161216415940648
   PubMed Web of Science ®Google Scholar
• JakobovitsSLJewellDPTravisSPInfliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006Aliment Pharmacol Ther20072591055106017439506
   PubMed Web of Science ®Google Scholar
• BermejoFLopez-SanromanAHinojosaJCastroLJuradoCGomez-BeldalABInfliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitisRev Esp Enferm Dig20049629410115255018
   PubMed Web of Science ®Google Scholar
• GornetJMCouveSHassaniZInfliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre studyAliment Pharmacol Ther200318217518112869077
   PubMed Web of Science ®Google Scholar